C. Kurtz

发表

Assessment of treatment response in chronic constipation clinical trials

S. Shiff, C. Ervin, S. Fehnel, 2014, Clinical and experimental gastroenterology.

Linaclotide inhibits colonic nociceptors and relieves abdominal pain via guanylate cyclase-C and extracellular cyclic guanosine 3',5'-monophosphate.

M. Currie, S. Brierley, L. Blackshaw, 2013, Gastroenterology.

GT160-246, a Toxin Binding Polymer for Treatment ofClostridium difficile Colitis

R. Barker, D. Acheson, C. Kurtz, 2001, Antimicrobial Agents and Chemotherapy.

Low-Dose Linaclotide (72 μg) for Chronic Idiopathic Constipation: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial

W. Chey, M. Currie, P. Schoenfeld, 2017, The American Journal of Gastroenterology.

Linaclotide improves abdominal pain and bowel habits in a phase IIb study of patients with irritable bowel syndrome with constipation.

M. Currie, A. Lembo, M. Baird, 2010, Gastroenterology.

Efficacy of linaclotide for patients with chronic constipation.

M. Currie, A. Lembo, J. Johnston, 2010, Gastroenterology.

Linaclotide Attenuates Visceral Organ Crosstalk: Role of Guanylate Cyclase-C Activation in Reversing Bladder-Colon Cross-Sensitization

B. Greenwood-Van Meerveld, C. Kurtz, P. Ge, 2018, The Journal of Pharmacology and Experimental Therapeutics.

Development of a synthetic live bacterial therapeutic for the human metabolic disease phenylketonuria

Adam B Fisher, K. West, M. Castillo, 2018, Nature Biotechnology.

Safety and pharmacodynamics of an engineered E. coli Nissle for the treatment of phenylketonuria: a first-in-human phase 1/2a study

W. S. Denney, J. Vockley, S. Sacharow, 2021, Nature Metabolism.

Translational Development of Microbiome‐Based Therapeutics: Kinetics of E. coli Nissle and Engineered Strains in Humans and Nonhuman Primates

W. S. Denney, S. Saha, A. Brennan, 2017, Clinical and translational science.

Responders vs clinical response: a critical analysis of data from linaclotide phase 3 clinical trials in IBS-C

M. Currie, S. Shiff, A. Lembo, 2014, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

Pilot Study on the Effect of Linaclotide in Patients With Chronic Constipation

D. Drossman, M. Currie, A. Lembo, 2009, The American Journal of Gastroenterology.

Genetically engineered E. coli Nissle attenuates hyperammonemia and prevents memory impairment in bile‐duct ligated rats

C. Rose, W. Querbes, C. Kurtz, 2021, Liver international : official journal of the International Association for the Study of the Liver.

The murine complement receptor gene family. IV. Alternative splicing of Cr2 gene transcripts predicts two distinct gene products that share homologous domains with both human CR2 and CR1.

S. Christensen, C. Kurtz, J. Weis, 1990, Journal of immunology.

Effects of products of activated leukocytes (lymphokines and monokines) on the growth of malignant trophoblast cells in vitro.

R. Berkowitz, D. Anderson, C. Kurtz, 1988, American journal of obstetrics and gynecology.

Effect of 5 days linaclotide on transit and bowel function in females with constipation-predominant irritable bowel syndrome.

A. Zinsmeister, M. Camilleri, M. Currie, 2007, Gastroenterology.

Chronic linaclotide treatment reduces colitis-induced neuroplasticity and reverses persistent bladder dysfunction.

Paul E. Miller, R. Feil, S. Brierley, 2018, JCI insight.

Linaclotide is a potent and selective guanylate cyclase C agonist that elicits pharmacological effects locally in the gastrointestinal tract.

M. Currie, C. Kurtz, G. Hannig, 2010, Life sciences.

An engineered bacterial therapeutic lowers urinary oxalate in preclinical models and in silico simulations of enteric hyperoxaluria

Ron B. Shmueli, M. Charbonneau, Nicholas G Horvath, 2022, Molecular systems biology.

Linaclotide, through activation of guanylate cyclase C, acts locally in the gastrointestinal tract to elicit enhanced intestinal secretion and transit.

M. Currie, C. Kurtz, G. Hannig, 2010, European journal of pharmacology.

Linaclotide Significantly Improved Abdominal Pain, Constipation and Global Assessments in Adults with Irritable Bowel Syndrome with Constipation: Results from a Large Twelve-Week, Randomized, Double-Blind, Placebo-Controlled Study

M. Currie, A. Lembo, M. Baird, 2008 .

Effect of linaclotide on severe abdominal symptoms in patients with irritable bowel syndrome with constipation.

M. Currie, S. Shiff, E. Quigley, 2014, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Gastrointestinal pain: Unraveling a novel endogenous pathway through uroguanylin/guanylate cyclase-C/cGMP activation

M. Currie, E. Ustinova, E. Liong, 2013, PAIN®.

An evaluation of the FDA Responder Endpoint for IBS‐C clinical trials: analysis of data from linaclotide Phase 3 clinical trials

L. Nelson, M. Currie, S. Shiff, 2013, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

Mo2054 Assessing Abdominal and Bowel Symptoms Using Adequate Relief Based Thresholds: Results From 2 Phase 3 Trials of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation

M. Camilleri, M. Currie, S. Shiff, 2013 .

Pharmacologic Properties, Metabolism, and Disposition of Linaclotide, a Novel Therapeutic Peptide Approved for the Treatment of Irritable Bowel Syndrome with Constipation and Chronic Idiopathic Constipation

M. Currie, C. Kurtz, G. Hannig, 2013, The Journal of Pharmacology and Experimental Therapeutics.

Linaclotide for Irritable Bowel Syndrome With Constipation: A 26-Week, Randomized, Double-blind, Placebo-Controlled Trial to Evaluate Efficacy and Safety

W. Chey, M. Currie, S. Shiff, 2012, The American Journal of Gastroenterology.

A 12-Week, Randomized, Controlled Trial With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Linaclotide in Irritable Bowel Syndrome With Constipation

M. Currie, S. Shiff, A. Lembo, 2012, The American Journal of Gastroenterology.

Guanylate cyclase C‐mediated antinociceptive effects of linaclotide in rodent models of visceral pain

M. Currie, E. Mayer, H. Eutamene, 2010, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

Effects of Single Dose Administration of MD-1100 on Safety, Tolerability, Exposure, and Stool Consistency in Healthy Subjects: 894

M. Currie, C. Kurtz, S. Mahajan-Miklos, 2005 .

The Effect of Psyllium Husk on Intestinal Microbiota in Constipated Patients and Healthy Controls

Gulzar Singh, R. Spiller, W. D. de Vos, 2019, International Journal of Molecular Sciences.

Two randomized trials of linaclotide for chronic constipation.

M. Currie, S. Shiff, A. Lembo, 2011, The New England journal of medicine.

MRP4 Modulation of the Guanylate Cyclase-C/cGMP Pathway: Effects on Linaclotide-Induced Electrolyte Secretion and cGMP Efflux

M. Currie, C. Lunte, C. Kurtz, 2015, The Journal of Pharmacology and Experimental Therapeutics.

Linaclotide in Chronic Idiopathic Constipation Patients with Moderate to Severe Abdominal Bloating: A Randomized, Controlled Trial

M. Currie, S. Shiff, A. Lembo, 2015, PloS one.

MRP 4 Modulation of the Guanylate Cyclase-C / cGMP Pathway : Effects on Linaclotide-Induced Electrolyte Secretion and cGMP Efflux s

M. Currie, C. Lunte, C. Kurtz, 2015 .

The impact of abdominal pain on global measures in patients with chronic idiopathic constipation, before and after treatment with linaclotide: a pooled analysis of two randomised, double-blind, placebo-controlled, phase 3 trials

M. Currie, L. Chang, S. Shiff, 2014, Alimentary pharmacology & therapeutics.

Psychometric validation of patient-reported outcome measures assessing chronic constipation

L. Nelson, S. Fehnel, M. Baird, 2014, Clinical and experimental gastroenterology.

Pharmacological Properties, Metabolism and Disposition of Linaclotide, a Novel Therapeutic Peptide Approved for the Treatment of Irritable Bowel Syndrome with Constipation and Chronic Idiopathic Constipation #

C. Kurtz, G. Hannig, D. James, 2012 .

Genetic organization of complement receptor-related genes in the mouse

S. Kingsmore, P. Leroy, M. Seldin, 1989, The Journal of experimental medicine.

Demonstration of differences in colonic volumes, transit, chyme consistency, and response to psyllium between healthy and constipated subjects using magnetic resonance imaging

L. Marciani, Gulzar Singh, R. Spiller, 2018, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

The murine complement receptor gene family. Analysis of mCRY gene products and their homology to human CR1.

M. Aegerter, C. Kurtz, J. Weis, 1989, Journal of immunology.

An engineered E. coli Nissle improves hyperammonemia and survival in mice and shows dose-dependent exposure in healthy humans

W. S. Denney, K. West, Y. Dagon, 2019, Science Translational Medicine.

Development of an engineered probiotic for the treatment of branched chain amino acid related metabolic diseases

Jianqin Gao, M. Castillo, P. Boyle, 2021 .

Developing a new class of engineered live bacterial therapeutics to treat human diseases

M. Charbonneau, C. Kurtz, Ning Li, 2020, Nature Communications.

Linaclotide Significantly Improved Bowel Habits and Relieved Abdominal Symptoms in Adults with Chronic Constipation: Data from a Large 4-Week, Randomized, Double-Blind, Placebo-Controlled Study

D. Drossman, M. Currie, A. Lembo, 2008 .

366 Guanylate Cyclase-C Expression Is Down-Regulated in Colonic Biopsies From Female Irritable Bowel Syndrome Patients With Constipation

Lin Chang, S. Brierley, C. Kurtz, 2016 .